9 October 2015 - CADTH is inviting stakeholder comments and feedback on the proposed framework to align drug expert committee recommendations to be used in both the CADTH Common Drug Review (CDR) and pan-Canadian Oncology Drug Review (pCODR) programs.

At the stakeholder engagement session held on February 5, 2015, CADTH announced its intent to create a single recommendation framework that is applied by its drug expert committees (the CADTH Canadian Drug Expert Committee [CDEC] and the CADTH pCODR Expert Review Committee [pERC]).

As part of the ongoing process to align the two programs, CADTH and the participating jurisdictions have agreed that the following three recommendation categories and terminology will be adopted for use in both CDR and pCODR:

• Reimburse
• Reimburse with clinical criteria and/or conditions
• Do not reimburse

For more details, go to: https://www.cadth.ca/cdr-update-issue-114